[IOICORP] YoY Cumulative Quarter Result on 31-Dec-2021 [#2]

Stock
[IOICORP] IOI CORPORATION BHD
Announcement Date
23-Feb-2022
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2022
Quarter
31-Dec-2021 [#2]
Profit Trend
QoQ- 178.21%
YoY- 21.89%
Quarter Report
Latest QR
Upcoming QR
IOICORP's Result
IOICORP's Financial Summary
View:
Show?
Cumulative Result
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Revenue 4,601,000 6,972,700 7,744,700 4,931,900 3,730,700 3,756,300 4,605,900 -0.01%
PBT 785,700 1,172,100 1,113,300 790,200 467,900 434,200 1,073,000 -5.05%
Tax -140,800 -284,000 -315,800 -144,600 -106,300 -97,400 -107,100 4.66%
NP 644,900 888,100 797,500 645,600 361,600 336,800 965,900 -6.50%
-
NP to SH 639,400 879,600 772,300 633,600 362,500 339,300 955,900 -6.47%
-
Tax Rate 17.92% 24.23% 28.37% 18.30% 22.72% 22.43% 9.98% -
Total Cost 3,956,100 6,084,600 6,947,200 4,286,300 3,369,100 3,419,500 3,640,000 1.39%
-
Net Worth 11,538,882 11,237,384 10,326,859 9,587,591 9,301,273 9,175,303 7,980,552 6.33%
Dividend
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Div 279,166 372,510 373,260 281,988 251,385 219,955 282,775 -0.21%
Div Payout % 43.66% 42.35% 48.33% 44.51% 69.35% 64.83% 29.58% -
Equity
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Net Worth 11,538,882 11,237,384 10,326,859 9,587,591 9,301,273 9,175,303 7,980,552 6.33%
NOSH 6,258,100 6,258,100 6,258,100 6,285,198 6,284,643 6,284,453 6,283,900 -0.06%
Ratio Analysis
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
NP Margin 14.02% 12.74% 10.30% 13.09% 9.69% 8.97% 20.97% -
ROE 5.54% 7.83% 7.48% 6.61% 3.90% 3.70% 11.98% -
Per Share
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
RPS 74.17 112.31 124.49 78.70 59.36 59.77 73.30 0.19%
EPS 10.31 14.16 12.40 10.11 5.77 5.40 15.21 -6.27%
DPS 4.50 6.00 6.00 4.50 4.00 3.50 4.50 0.00%
NAPS 1.86 1.81 1.66 1.53 1.48 1.46 1.27 6.56%
Adjusted Per Share Value based on latest NOSH - 6,258,100
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
RPS 74.19 112.43 124.88 79.53 60.16 60.57 74.27 -0.01%
EPS 10.31 14.18 12.45 10.22 5.85 5.47 15.41 -6.47%
DPS 4.50 6.01 6.02 4.55 4.05 3.55 4.56 -0.22%
NAPS 1.8606 1.812 1.6652 1.546 1.4998 1.4795 1.2869 6.33%
Price Multiplier on Financial Quarter End Date
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Date 29/12/23 30/12/22 31/12/21 31/12/20 31/12/19 31/12/18 29/12/17 -
Price 3.93 4.05 3.73 4.37 4.61 4.45 4.54 -
P/RPS 5.30 3.61 3.00 5.55 7.77 7.45 6.19 -2.55%
P/EPS 38.13 28.59 30.05 43.22 79.92 82.42 29.85 4.16%
EY 2.62 3.50 3.33 2.31 1.25 1.21 3.35 -4.01%
DY 1.15 1.48 1.61 1.03 0.87 0.79 0.99 2.52%
P/NAPS 2.11 2.24 2.25 2.86 3.11 3.05 3.57 -8.38%
Price Multiplier on Announcement Date
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Date 23/02/24 28/02/23 23/02/22 23/02/21 18/02/20 20/02/19 23/02/18 -
Price 3.99 3.83 4.42 4.24 4.50 4.73 4.79 -
P/RPS 5.38 3.41 3.55 5.39 7.58 7.91 6.54 -3.20%
P/EPS 38.71 27.03 35.60 41.93 78.02 87.61 31.49 3.49%
EY 2.58 3.70 2.81 2.38 1.28 1.14 3.18 -3.42%
DY 1.13 1.57 1.36 1.06 0.89 0.74 0.94 3.11%
P/NAPS 2.15 2.12 2.66 2.77 3.04 3.24 3.77 -8.93%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment